PCRX · Pacira BioSciences, Inc.
$23.00
-0.18 (-0.78%)
At close · Aug 14
Market Cap
$916.82M
Shares
39.86M
Pacira BioSciences, Inc. Earnings Call Transcripts
Every quarterly earnings call for Pacira BioSciences, Inc. (PCRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲31.1%
$167.47M
−$693,000
'22 Q3
22-11-14
▲8%
$171.96M
−$10.10M
'22 Q4
23-01-05
▲1.5%
$160.34M
−$19.54M
'23 Q1
23-05-03
▲0%
$169.47M
$25.76M
'23 Q2
23-08-02
▼2.1%
$163.93M
$10.86M
'23 Q3
23-11-02
▲5.4%
$181.24M
$24.87M
'23 Q4
24-02-29
▲4.2%
$167.12M
$8.98M
'24 Q1
24-05-07
▲5%
$178.02M
$18.89M
'24 Q2
24-07-30
▲2.8%
$168.57M
−$143.47M
'24 Q3
24-11-06
▲3.3%
$187.25M
$16.04M
'24 Q4
25-02-27
▲1.1%
$168.92M
$4.81M
'25 Q1
25-05-08
▲1.7%
$181.10M
−$4.85M
'25 Q2
25-08-05
▲6.5%
$179.52M
$5.43M
'25 Q3
25-11-06
▲5.1%
$196.87M
$1.64M
'25 Q4
26-02-26
▲5%
$177.38M
$2.92M
'26 Q1
26-04-30
LATEST
▲6.2%
$192.40M
$4.65M
'26 Q2
26-08-04
Earnings call
FY26 · Q2
2026-08-04
Pacira BioSciences, Inc. Q2 FY2026 Earnings Call
Confident tone
Pipeline catalysts and clinical readouts
Exparel commercial performance and market access
IOVERA divestiture and Zimmer Biomet partnership
Revenue
$192.40M
▲ 6.2% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Pacira BioSciences, Inc. Q1 FY2026 Earnings Call
Confident tone
Five by 30 strategy execution
PCRX201 gene therapy pipeline
EXPAREL commercial performance and growth
Revenue
$177.38M
▲ 5% YoY Diluted EPS
$0.07
▼ 30% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-26
Pacira BioSciences, Inc. Q4 FY2025 Earnings Call
Confident tone
5x30 strategy and 2026 guidance
Pipeline and clinical milestones
Exparel (Expiril) commercial performance
Revenue
$196.87M*
▲ 5.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Pacira BioSciences, Inc. Q3 FY2025 Earnings Call
Confident tone
5x30 strategy
Expiril commercial momentum
GPO discounting and pricing pressure
Revenue
$179.52M
▲ 6.5% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Pacira BioSciences, Inc. Q2 FY2025 Earnings Call
Confident tone
EXPAREL commercial performance
ZILRETTA and J&J partnership
CMS reimbursement and policy
Revenue
$181.10M
▲ 1.7% YoY Diluted EPS
$-0.11
▼ 128.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Pacira BioSciences, Inc. Q1 FY2025 Earnings Call
Positive tone
EXPAREL Litigation Settlement and IP
PCRX-201 Pipeline and HCAd Platform
No Pain Reimbursement and EXPAREL Growth
Revenue
$168.92M
▲ 1.1% YoY Diluted EPS
$0.10
▼ 47.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Pacira BioSciences, Inc. Q4 FY2024 Earnings Call
Confident tone
iovera Reimbursement and SmartTip Launch
5/30 Strategy and Long-Term Growth Plan
Gross Margin and Operating Expense Outlook
Revenue
$187.25M*
▲ 3.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Pacira BioSciences, Inc. Q3 FY2024 Earnings Call
Positive tone
NOPAIN reimbursement and EXPAREL access
iovera growth and reimbursement
PCRX-201 gene therapy program
Revenue
$168.57M
▲ 2.8% YoY Diluted EPS
$-3.11
▼ 1452.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Pacira BioSciences, Inc. Q2 FY2024 Earnings Call
Confident tone
EXPAREL lower extremity nerve block rollout
NOPAIN Act reimbursement preparation
EXPAREL patent litigation and generic threat
Revenue
$178.02M
▲ 5% YoY Diluted EPS
$0.39
▼ 23.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Pacira BioSciences, Inc. Q1 FY2024 Earnings Call
Positive tone
NOPAIN Reimbursement and Outpatient Opportunity
ZILRETTA and iovera Performance
PCRX-201 Gene Therapy Pipeline
Revenue
$167.12M
▲ 4.2% YoY Diluted EPS
$0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Pacira BioSciences, Inc. Q4 FY2023 Earnings Call
Positive tone
EXPAREL financial performance
NOPAIN Act and reimbursement
EXPAREL lower extremity nerve block launch
Revenue
$181.24M*
▲ 5.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Pacira BioSciences, Inc. Q3 FY2023 Earnings Call
Revenue
$163.93M
▼ 2.1% YoY Diluted EPS
$0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Pacira BioSciences, Inc. Q2 FY2023 Earnings Call
Revenue
$169.47M
▲ 0% YoY Diluted EPS
$0.51
▲ 27.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Pacira BioSciences, Inc. Q1 FY2023 Earnings Call
Revenue
$160.34M
▲ 1.5% YoY Diluted EPS
$-0.43
▼ 386.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Pacira BioSciences, Inc. Q4 FY2022 Earnings Call
Revenue
$171.96M*
▲ 8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Pacira BioSciences, Inc. Q3 FY2022 Earnings Call
Revenue
$167.47M
▲ 31.1% YoY Diluted EPS
$-0.02
▼ 105.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-09-13
Pacira BioSciences, Inc. Q2 FY2022 Earnings Call
Revenue
$169.41M
▲ 24.9% YoY Diluted EPS
$0.40
▼ 4.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-06-14
Pacira BioSciences, Inc. Q1 FY2022 Earnings Call
Revenue
$157.99M
▲ 32.7% YoY Diluted EPS
$0.15
▼ 34.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-15
Pacira BioSciences, Inc. Q4 FY2021 Earnings Call
Revenue
$159.19M*
▲ 21.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-12
Pacira BioSciences, Inc. Q3 FY2021 Earnings Call
Revenue
$127.72M
▲ 8.7% YoY Diluted EPS
$0.39
▼ 86.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Pacira BioSciences, Inc. Q2 FY2021 Earnings Call
Revenue
$135.59M
▲ 79.6% YoY Diluted EPS
$0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Pacira BioSciences, Inc. Q1 FY2021 Earnings Call
Revenue
$119.03M
▲ 12.6% YoY Diluted EPS
$0.23
▲ 21.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-07
Pacira BioSciences, Inc. Q4 FY2020 Earnings Call
Revenue
$130.97M
▲ 7% YoY Diluted EPS
$0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-07
Pacira BioSciences, Inc. Q3 FY2020 Earnings Call
Revenue
$117.48M
▲ 12.2% YoY Diluted EPS
$2.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Pacira BioSciences, Inc. Q2 FY2020 Earnings Call
Revenue
$75.50M
▼ 26.4% YoY Diluted EPS
$-0.17
▼ 383.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Pacira BioSciences, Inc. Q1 FY2020 Earnings Call
Revenue
$105.68M
▲ 15.7% YoY Diluted EPS
$0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Pacira BioSciences, Inc. Q4 FY2019 Earnings Call
Revenue
$122.42M
▲ 28.7% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 earnings calls
Key facts
CIK
1396814
CUSIP
695127100
13F (30d)
236 filings
232 filers
Visit website
Investor relations